Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Arctic Moss Berry contains methylarbutin (0.80-8.00 mg/g), quercetin, and hyperoside that provide antioxidant activity through free radical scavenging mechanisms. The phenolic compounds exhibit anti-inflammatory effects by modulating NF-κB pathways and inhibiting digestive enzymes like α-amylase.
Reported Benefits (Provisional)
Origin & History
Arctic Moss Berry is a resilient fruit found across Arctic tundra regions, including northern Scandinavia, Canada, Alaska, and Russia. Thriving in cold, nutrient-poor environments, this berry is a source of potent bioactive compounds. It is valued for its capacity to support cognitive function, immune resilience, and vision protection.
Research Narrative (Provisional)
Emerging research, including in vitro and animal studies, indicates Arctic Moss Berry's rich anthocyanin and polyphenol content contributes to its antioxidant and neuroprotective effects. Studies are exploring its potential for cognitive function, immune resilience, and cardiovascular health. The provided studies offer preliminary insights into its bioactive compounds.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Prebiotic Fiber - Vitamin C - Vitamin E - Manganese - Iron - Potassium - Anthocyanins (delphinidin, malvidin) - Polyphenols (resveratrol, quercetin) - Flavonoids - Plant sterols - Omega-3 precursors
Reported Mechanism (Provisional)
Methylarbutin and other phenolic compounds donate electrons to neutralize free radicals, converting them to stable molecules. The bioactive compounds modulate NF-κB inflammatory pathways and inhibit α-amylase enzyme activity through molecular binding similar to acarbose. Anthocyanins like delphinidin 3-O-galactoside promote cellular apoptosis and cycle arrest via AP-1/NF-κB signaling inhibition.
Clinical Narrative (Provisional)
Current evidence for Arctic Moss Berry is limited to phytochemical analysis and in vitro studies rather than human clinical trials. Research has identified significant phenolic content variation across environments, with PCA analysis explaining 69.13% of metabolite variability. In vitro studies demonstrate membrane destabilization effects against E. coli and Staphylococcus aureus, though specific quantified outcomes for Arctic species are lacking. The evidence base consists primarily of preliminary laboratory research without controlled human trials.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.